Evidence map›Paper›PMID 32950294›Full record

ArticleEuropean urology2021

The Link Between the Gut Microbiome and Response to Immune Checkpoint Inhibitors in Renal Cell Carcinoma.

Antoine Desilets, Arielle Elkrief, Bertrand Routy

Registry-linked trialAbstract readEditorialComment
PubMed Publisher
In one paragraph

Article in European urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05119010 (A Pilot Study Evaluating a Ketogenic Diet Concomitant to Nivolumab and Ipilimumab in Patients With Metastatic Renal Cell Carcinoma), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05119010 naterminatednot on this mapstarted 2023, after this paper: background citation

A Pilot Study Evaluating a Ketogenic Diet Concomitant to Nivolumab and Ipilimumab in Patients With Metastatic Renal Cell Carcinoma

TypeinterventionalSponsorGustave Roussy, Cancer Campus, Grand ParisRan2023 to 2024Enrolled3ConditionsMetastatic Renal Cell CarcinomaArmsContinuous ketogenic diet, Discontinuous ketogenic diet, beta-hydroxybutyrate (BHB) supplementation
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. The oncobiome; what, so what, now what?Microbiome research reports · 2025
    Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Antoine DesiletsHematology-Oncology Division, Department of Medicine, Centre Hospitalier de l'Université de Montreal, Montreal, Canada; Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal, Canada.
Arielle ElkriefHematology-Oncology Division, Department of Medicine, Centre Hospitalier de l'Université de Montreal, Montreal, Canada; Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal, Canada.
Bertrand RoutyHematology-Oncology Division, Department of Medicine, Centre Hospitalier de l'Université de Montreal, Montreal, Canada; Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal, Canada. Electronic address: bertrand.routy@umontreal.ca.
Centre Hospitalier de l’Université de Montréal · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Carcinoma, Renal CellGastrointestinal MicrobiomeKidney NeoplasmsMicrobiotaHumansImmune Checkpoint InhibitorsImmune Checkpoint Inhibitors

Identifiers

PMID32950294
OpenAlexW3087662097

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.